The present application is concerned with pharmaceutically active compounds. The disclosure provides compounds as well as their compositions and methods of use. The compounds modulate PD-1/PD-L1 protein/protein interaction and are useful in the treatment of various diseases including infectious diseases and cancer.   BACKGROUND OF THE INVENTION

The immune system plays an important role in controlling and eradicating diseases such as cancer. However, cancer cells often develop strategies to evade or to suppress the immune system in order to favor their growth. One such mechanism is altering the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al, J. Clinical Oncology 2015, 1-9). Blocking the signaling of an inhibitory immune checkpoint, such as PD-1, has proven to be a promising and effective treatment modality.

Programmed cell death-1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al, Annu. Rev. Immunol 2005, 23:515–548; Okazaki and Honjo, Trends Immunol 2006,  (4):195-201). It functions as an intrinsic negative feedback system to prevent the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. In addition, PD- 1 is also known to play a critical role in the suppression of antigen-specific T cell response in diseases like cancer and viral infection (Sharpe et al, Nat Immunol 20078, 239–245; Postow et al, J. Clinical Oncol 2015, 1-9).

  The structure of PD-1 consists of an extracellular immunoglobulin variable-like

domain followed by a transmembrane region and an intracellular domain (Parry et al, Mol Cell Biol 2005, 9543–9553). The intracellular domain contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates T cell receptor- mediated signals. PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al, Mol Cell Biol 2005, 9543–9553; Latchman et al, Nat Immunol 2001, 2, 261–268), and they differ in their expression patterns. PD-L1 protein is upregulated on macrophages and dendritic cells in response to lipopolysaccharide and GM-CSF treatment, and on T cells and B cells upon T cell receptor and B cell receptor signaling. PD-L1 is also highly expressed on almost all tumor cells, and the expression is further increased after IFN-γ treatment (Iwai et al, PNAS2002, 99(19):12293-7; Blank et al, Cancer Res 2004, 64(3):1140-5). In fact, tumor PD- L1 expression status has been shown to be prognostic in multiple tumor types (Wang et al, Eur J Surg Oncol 2015; Huang et al, Oncol Rep 2015; Sabatier et al, Oncotarget 2015, 6(7): 5449–5464). PD-L2 expression, in contrast, is more restricted and is expressed mainly by dendritic cells (Nakae et al, J Immunol 2006, 177:566-73). Ligation of PD-1 with its ligands PD-L1 and PD-L2 on T cells delivers a signal that inhibits IL-2 and IFN-γ production, as well as cell proliferation induced upon T cell receptor activation (Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000, 192(7):1027-34). The mechanism involves recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling such as Syk and Lck phosphorylation (Sharpe et al, Nat Immunol 2007, 8, 239–245).

Activation of the PD-1 signaling axis also attenuates PKC-θ activation loop phosphorylation, which is necessary for the activation of NF- ^B and AP1 pathways, and for cytokine production such as IL-2, IFN-γ and TNF (Sharpe et al, Nat Immunol 2007, 8, 239–245; Carter et al, Eur J Immunol 2002, 32(3):634-43; Freeman et al, J Exp Med 2000,

192(7):1027-34).

Several lines of evidence from preclinical animal studies indicate that PD-1 and its ligands negatively regulate immune responses. PD-1-deficient mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al, Immunity 1999, 11:141–151; Nishimura et al, Science 2001, 291:319–322). Using an LCMV model of chronic infection, it has been shown that PD-1/PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus-specific CD8 T cells (Barber et al, Nature 2006, 439, 682-7). Together, these data support the development of a therapeutic approach to block the PD-1-mediated inhibitory signaling cascade in order to augment or“rescue” T cell response. Accordingly, there is a need for new compounds that block PD-1/PD-L1 protein/protein interaction. SUMMARY

The present disclosure rovides a com ound of Formula I’:

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein constituent variables are defined herein.

The present disclosure provides, inter alia, a compound of Formula (I):

or a pharmaceutically ariables are defined herein.

The present disclosure further provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt or a stereoisomer thereof, and one or more pharmaceutically acceptable excipient or carrier.

The present disclosure further provides methods of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound disclosed herein, or a pharmaceutically acceptable salt or a stereoisomer thereof.

The present disclosure further provides methods of treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of disclosed herein, or a pharmaceutically acceptable salt or a stereoisomer thereof.

The present disclosure further provides methods of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt or a stereoisomer thereof. DETAILED DESCRIPTION

I. Compounds

The present disclosure provides, inter alia, a compound of Formula (I’):  

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

G has Formula (I’e) or (I’b)

when G is of Formula (I’a), the atoms on ring C, to which the substituent R ⁴ and ring B are attached can be either carbon or nitrogen; and is a single bond or a double bond;

when G is of Formula (I’b), ring B and ring C are joined together through a quaternary ring carbon atom to form a spiro structure and ring B and ring C are each independently 4- to 14- membered heterocycloalkyl or C3-14 cycloalkyl;

L ¹ is a bond,–(CR ¹⁴ R ¹⁵ ) _t C(O)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)(CR ¹⁴ R ¹⁵ ) _t -,– (CR ¹⁴ R ¹⁵ )tC(=S)NR ¹³ (CR ¹⁴ R ¹⁵ )t-, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(=S)(CR ¹⁴ R ¹⁵ )t -,–

(CR ¹⁴ R ¹⁵ ) _t C(=NR ¹³ )NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(=NR ¹³ )(CR ¹⁴ R ¹⁵ ) _t -,–

(CR ¹⁴ R ¹⁵ )tC(=NOR ¹³ )NR ¹³ (CR ¹⁴ R ¹⁵ )t-, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(=NOR ¹³ )(CR ¹⁴ R ¹⁵ )t -,–

(CR ¹⁴ R ¹⁵ ) _t C(=NCN)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(=NCN)(CR ¹⁴ R ¹⁵ ) _t -, O, -(CR ¹⁴ R ¹⁵ ) _p -, - (CR ¹⁴ R ¹⁵ )p-O-, -O(CR ¹⁴ R ¹⁵ )p-, -(CR ¹⁴ R ¹⁵ )p-O-(CR ¹⁴ R ¹⁵ )p-, S, -(CR ¹⁴ R ¹⁵ )p-S-, -S(CR ¹⁴ R ¹⁵ )p-, - (CR ¹⁴ R ¹⁵ ) _p -S-(CR ¹⁴ R ¹⁵ ) _p -, -NR ¹³ -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -NH-, - ( _CR ¹⁴ _R ¹⁵ _)tNH(CR ¹⁴ _R ¹⁵ _{)t-, -CR} ¹³ _=CR ¹³ _-, ^{C C} _{, -SO2-, -(CR} ¹⁴ _R ¹⁵ _)tSO2(CR ¹⁴ _R ¹⁵ _{)t -, -} (CR ¹⁴ R ¹⁵ )tSO2NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tNR ¹³ SO2(CR ¹⁴ R ¹⁵ )t -, - (CR ¹⁴ R ¹⁵ ) _t NR ¹³ SO ₂ NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)O(CR ¹⁴ R ¹⁵ ) _t -, -NR ¹³ C(O)O-, - (CR ¹⁴ R ¹⁵ )tO(CO)NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -O(CO)NR ¹³ -,–NR ¹³ C(O)NR ¹³ - or - (CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)NR ¹³ (CR ¹⁴ R ¹⁵ )t;

L ³ is a bond,–(CR ¹⁴ R ¹⁵ ) _t C(O)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)(CR ¹⁴ R ¹⁵ ) _t -,– (CR ¹⁴ R ¹⁵ )tC(=S)NR ¹³ (CR ¹⁴ R ¹⁵ )t-, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(=S)(CR ¹⁴ R ¹⁵ )t -,–

(CR ¹⁴ R ¹⁵ ) _t C(=NR ¹³ )NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(=NR ¹³ )(CR ¹⁴ R ¹⁵ ) _t -,–

(CR ¹⁴ R ¹⁵ )tC(=NOR ¹³ )NR ¹³ (CR ¹⁴ R ¹⁵ )t-, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(=NOR ¹³ )(CR ¹⁴ R ¹⁵ )t -,–

(CR ¹⁴ R ¹⁵ ) _t C(=NCN)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(=NCN)(CR ¹⁴ R ¹⁵ ) _t -, O, -(CR ¹⁴ R ¹⁵ ) _p - , -(CR ¹⁴ R ¹⁵ )p-O-, -O(CR ¹⁴ R ¹⁵ )p-, -(CR ¹⁴ R ¹⁵ )p-O-(CR ¹⁴ R ¹⁵ )p-, S, -(CR ¹⁴ R ¹⁵ )p-S-, -S(CR ¹⁴ R ¹⁵ )p- , -(CR ¹⁴ R ¹⁵ ) _p -S-(CR ¹⁴ R ¹⁵ ) _p -, -NR ¹³ -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -NH-, - ( _CR ¹⁴ _R ¹⁵ _)tNH(CR ¹⁴ _R ¹⁵ _{)t-, -CR} ¹³ _=CR ¹³ _-, ^{C C} _{, -SO2-, -(CR} ¹⁴ _R ¹⁵ _)tSO2(CR ¹⁴ _R ¹⁵ _{)t -, -} (CR ¹⁴ R ¹⁵ )tSO2NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tNR ¹³ SO2(CR ¹⁴ R ¹⁵ )t -, - (CR ¹⁴ R ¹⁵ )tNR ¹³ SO2NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)O(CR ¹⁴ R ¹⁵ )t -, -NR ¹³ C(O)O-, - (CR ¹⁴ R ¹⁵ )tO(CO)NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -O(CO)NR ¹³ -,–NR ¹³ C(O)NR ¹³ - or - (CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t ;

ring A is C6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C _3-14 cycloalkyl;

ring B is C6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C _3-14 cycloalkyl;

ring C is C6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C _3-14 cycloalkyl;

each R ¹³ is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, CN, halo, OH, - COOH, NH2, -NHC1-4 alkyl and–N(C1-4 alkyl)2;

R ¹⁴ and R ¹⁵ are each independently selected from H, halo, CN, OH, -COOH, C _1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ¹⁴ or R ¹⁵ are each optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

or R ¹⁴ and R ¹⁵ taken together with the carbon atom to which they are attached form C _3-6 cycloalkyl or 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

R ⁴ is H, halo, oxo, CN, C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C _2-6 alkynyl, C _1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl, or C _3-6 cycloalkyl, wherein the C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C _2-6 alkynyl, 4- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl and C3-6 cycloalkyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, C3-6

cycloalkyl, 5- to 6-membered heteroaryl, phenyl, NH ₂ , -NHR ⁸ , -NR ⁸ R ⁸ , C(O)R ⁸ ,

C(O)NR ⁸ R ⁸ , OC(O)NR ⁸ R ⁸ , NR ⁸ C(O)R ⁸ , NR ⁸ C(O)OR ⁸ , NR ⁸ C(O)NR ⁸ R ⁸ , NR ⁸ S(O)2R ⁸ , NR ⁸ S(O) ₂ NR ⁸ R ⁸ , S(O)R ⁸ , S(O) ₂ R ⁸ , and S(O) ₂ NR ⁸ R ⁸ , wherein each R ⁸ is independently H or C1-6 alkyl;

R ⁵ , R ⁶ and R ³¹ are each independently selected from halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered

heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, CN, NO2, OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NR ^a )NR ^a R ^a , NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O)2R ^a , NR ^a S(O) ₂ NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O) ₂ R ^a , C(O)NR ^a S(O) ₂ R ^a , NR ^a C(=NR ^a )R ^a ,

S(O)2NR ^a C(O)R ^a , -P(O)R ^a R ^a , -P(O)(OR ^a )(OR ^a ), -B(OH)2, -B(OR ^a )2, and S(O)2NR ^a R ^a , wherein the C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ⁵ , R ⁶ and R ³¹ are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents;

or two adjacent R ⁵ substituents on ring B, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6- membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ⁵ substituents on the same ring carbon atom of ring B, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, or a spiro C _3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two adjacent R ⁶ substituents on ring A, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents; or two R ⁶ substituents on the same ring carbon atom of the ring A, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two adjacent R ³¹ substituents on ring C, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ³¹ substituents on the same ring carbon atom of ring C, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, B, P, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

each R ^a is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^a are each optionally substituted with 1, 2 or 3 independently selected R ^d substituents; each R ^b substituent is independently selected from halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, CN, OH, NH2, NO2, NHOR ^c , OR ^c , SR ^c , C(O)R ^c , C(O)NR ^c R ^c , C(O)OR ^c , OC(O)R ^c , OC(O)NR ^c R ^c , C(=NR ^c )NR ^c R ^c , NR ^c C(=NR ^c )NR ^c R ^c , NR ^c C(=NOH)NR ^c R ^c , NR ^c C(=NCN)NR ^c R ^c , NHR ^c , NR ^c R ^c , NR ^c C(O)R ^c , NR ^c C(O)OR ^c , NR ^c C(O)NR ^c R ^c , NR ^c S(O)R ^c , NR ^c S(O)2R ^c ,

NR ^c S(O) ₂ NR ^c R ^c , S(O)R ^c , S(O)NR ^c R ^c , S(O) ₂ R ^c , C(O)NR ^c S(O) ₂ R ^c , NR ^c C(=NR ^c )R ^c ,

S(O)2NR ^c C(O)R ^c , -P(O)R ^c R ^c , -P(O)(OR ^c )(OR ^c ), -B(OH)2, -B(OR ^c )2, and S(O)2NR ^c R ^c ;

wherein the C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _1-6 haloalkyl, C _1-6 haloalkoxy, C _6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^b are each further optionally substituted with 1, 2, or 3 independently selected R ^d substituents;

or two R ^b substituents attached to the same ring carbon atom taken together with the ring carbon atom to which they are attached form spiro C _3-6 cycloalkyl or spiro 4- to 7- membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^f substituents;

each R ^c is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^c are each optionally substituted with 1, 2 or 3 independently selected R ^f substituents; each R ^f is independently selected from C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, halo, CN, NHOR ^g , OR ^g , SR ^g , C(O)R ^g , C(O)NR ^g R ^g , C(O)OR ^g , OC(O)R ^g , OC(O)NR ^g R ^g , NHR ^g , NR ^g R ^g , NR ^g C(O)R ^g , NR ^g C(O)NR ^g R ^g , NR ^g C(O)OR ^g , C(=NR ^g )NR ^g R ^g , NR ^g C(=NR ^g )NR ^g R ^g ,

NR ^g C(=NOH)NR ^g R ^g , NR ^g C(=NCN)NR ^g R ^g , S(O)R ^g , S(O)NR ^g R ^g , S(O) ₂ R ^g , NR ^g S(O) ₂ R ^g , NR ^g S(O)2NR ^g R ^g , C(O)NR ^g S(O)2R ^g , NR ^g C(=NR ^g )R ^g , S(O)2NR ^g C(O)R ^g , -P(O)R ^g R ^g , - P(O)(OR ^g )(OR ^g ), -B(OH) ₂ , -B(OR ^g ) ₂ , and S(O) ₂ NR ^g R ^g ; wherein the C _1-6 alkyl, C _1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^f are each optionally substituted with 1, 2 or 3 independently selected R ⁿ substituents;

each R ⁿ is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, C6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, NHOR ^o , OR ^o , SR ^o , C(O)R ^o , C(O)NR ^o R ^o , C(O)OR ^o , OC(O)R ^o , OC(O)NR ^o R ^o , NHR ^o , NR ^o R ^o , NR ^o C(O)R ^o , NR ^o C(O)NR ^o R ^o , NR ^o C(O)OR ^o , C(=NR ^o )NR ^o R ^o , NR ^o C(=NR ^o )NR ^o R ^o , S(O)R ^o , S(O)NR ^o R ^o , S(O) ₂ R ^o , NR ^o S(O) ₂ R ^o ,

NR ^o S(O)2NR ^o R ^o , C(O)NR ^o S(O)2R ^o , NR ^o C(=NR ^o )R ^o , S(O)2NR ^o C(O)R ^o , -P(O)R ^o R ^o , - P(O)(OR ^o )(OR ^o ), -B(OH) ₂ , -B(OR ^o ) ₂ , and S(O) ₂ NR ^o R ^o , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ⁿ is optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

each R ^d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR ^e , OR ^e , SR ^e , C(O)R ^e , C(O)NR ^e R ^e , C(O)OR ^e , OC(O)R ^e , OC(O)NR ^e R ^e , NHR ^e , NR ^e R ^e , NR ^e C(O)R ^e , NR ^e C(O)NR ^e R ^e , NR ^e C(O)OR ^e , C(=NR ^e )NR ^e R ^e , NR ^e C(=NR ^e )NR ^e R ^e , NR ^e C(=NOH)NR ^e R ^e , NR ^e C(=NCN)NR ^e R ^e , S(O)R ^e , S(O)NR ^e R ^e , S(O) ₂ R ^e , NR ^e S(O) ₂ R ^e , NR ^e S(O) ₂ NR ^e R ^e , C(O)NR ^e S(O) ₂ R ^e , NR ^e C(=NR ^e )R ^e , S(O)2NR ^e C(O)R ^e , -P(O)R ^e R ^e , -P(O)(OR ^e )(OR ^e ), -B(OH)2, -B(OR ^e )2, and S(O)2NR ^e R ^e , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _6-10 aryl, 5-10 membered heteroaryl, C _3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^d are each optionally substituted with 1, 2, or3 independently selected R ^f substituents;

each R ^e is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^e are each optionally substituted with 1, 2 or 3 independently selected R ^f substituents; each R ^g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, wherein the C _1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^g are each optionally substituted with 1, 2, or 3 independently selected R ^p substituents;

each R ^p is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, halo, CN, NHOR ^r , OR ^r , SR ^r , C(O)R ^r , C(O)NR ^r R ^r , C(O)OR ^r , OC(O)R ^r , OC(O)NR ^r R ^r , NHR ^r , NR ^r R ^r , NR ^r C(O)R ^r , NR ^r C(O)NR ^r R ^r , NR ^r C(O)OR ^r , C(=NR ^r )NR ^r R ^r , NR ^r C(=NR ^r )NR ^r R ^r , NR ^r C(=NOH)NR ^r R ^r , NR ^r C(=NCN)NR ^r R ^r , S(O)R ^r , S(O)NR ^r R ^r , S(O)2R ^r , NR ^r S(O)2R ^r , NR ^r S(O)2NR ^r R ^r ,

C(O)NR ^r S(O)2R ^r , NR ^r C(=NR ^r )R ^r , S(O)2NR ^r C(O)R ^r , -P(O)R ^r R ^r , -P(O)(OR ^r )(OR ^r ), -B(OH)2, - B(OR ^r ) ₂ , and S(O) ₂ NR ^r R ^r , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6- ₁₀ aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl- and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R ^p is optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or any two R ^a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 independently selected R ^h substituents;

each R ^h is independently selected from C _1-6 alkyl, C _1-6 haloalkyl, C _1-6 haloalkoxy, C _3- 10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered

heterocycloalkyl)-C1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR ⁱ , SR ⁱ , NHOR ⁱ , C(O)R ⁱ , C(O)NR ⁱ R ⁱ , C(O)OR ⁱ , OC(O)R ⁱ , OC(O)NR ⁱ R ⁱ , NHR ⁱ , NR ⁱ R ⁱ ,

NR ⁱ C(O)R ⁱ , NR ⁱ C(O)NR ⁱ R ⁱ , NR ⁱ C(O)OR ⁱ , C(=NR ⁱ )NR ⁱ R ⁱ , NR ⁱ C(=NR ⁱ )NR ⁱ R ⁱ ,

NR ⁱ S(O)2NR ⁱ R ⁱ , C(O)NR ⁱ S(O)2R ⁱ , NR ⁱ C(=NR ⁱ )R ⁱ , S(O)2NR ⁱ C(O)R ⁱ , P(O)R ⁱ R ⁱ , - P(O)(OR ⁱ )(OR ⁱ ), -B(OH)2, -B(OR ⁱ )2, and S(O)2NR ⁱ R ⁱ , wherein the C1-6 alkyl, C1-6 haloalkyl, C _1-6 haloalkoxy, C _3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C _6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^h are each optionally substituted by 1, 2, or 3 independently selected R ^j substituents;

each R ^j is independently selected from C _1-4 alkyl, C _3-10 cycloalkyl, C _6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, C _1-4 haloalkoxy, CN, NHOR ^k , OR ^k , SR ^k , C(O)R ^k , C(O)NR ^k R ^k , C(O)OR ^k , OC(O)R ^k , OC(O)NR ^k R ^k , NHR ^k , NR ^k R ^k , NR ^k C(O)R ^k , NR ^k C(O)NR ^k R ^k , NR ^k C(O)OR ^k , C(=NR ^k )NR ^k R ^k , NR ^k C(=NR ^k )NR ^k R ^k , S(O)R ^k , S(O)NR ^k R ^k , S(O) ₂ R ^k , NR ^k S(O) ₂ R ^k ,

NR ^k S(O)2NR ^k R ^k , C(O)NR ^k S(O)2R ^k , NR ^k C(=NR ^k )R ^k , S(O)2NR ^k C(O)R ^k , P(O)R ^k R ^k , - P(O)(OR ^k )(OR ^k ), -B(OH) ₂ , -B(OR ^k ) ₂ , and S(O) ₂ NR ^k R ^k , wherein the C _1-4 alkyl, C _3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C2-4 alkenyl, C _1-4 haloalkyl, and C _1-4 haloalkoxy of R ^j are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or two R ^h groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;

or any two R ^c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ⁱ substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents, or 1, 2, or 3 independently selected R ^q substituents;

or any two R ^k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents, or 1, 2, or 3 independently selected R ^q substituents; or any two R ^o substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents; and

or any two R ^r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

each R ⁱ , R ^k , R ^o or R ^r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C _6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C _1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C _6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C _2-4 alkenyl, and C2-4 alkynyl of R ⁱ , R ^k , R ^o or R ^r are each optionally substituted with 1, 2 or 3 R ^q substituents;

each R ^q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR ¹² and NR ¹² R ¹² , wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R ^q are each optionally substituted with halo, OH, CN, -COOH, NH ₂ , C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C1-4 haloalkoxy, phenyl, C3-10 cycloalkyl, 5- or 6-membered heteroaryl and 4-6 membered heterocycloalkyl and each R ¹² is independently C _1-6 alkyl;

the subscript n is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

the subscript m is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

each subscript p is independently an integer of 1, 2, 3 or 4;

each subscript t is independently an integer of 0, 1, 2, 3 or 4;

the subscript u is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

with the provisos:

wherein each R ⁹ is independently (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl and each R ¹¹ is independently H, halo, CN, C _1-6 alkyl, C _1-6 alkoxy, - NHC1-6 alkyl or benzyloxy, wherein the C1-6 alkyl, C1-6 alkoxy, -NHC1-6 alkyl and benzyloxy of R ¹¹ are each optionally substituted with halo, CN, C _1-6 alkyl or C _1-6 alkoxy;

independently (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; each R ¹¹ is independently H or C1-6 alkyl and R ¹⁰ is H, C1-6 alkoxy, benzyloxy, morpholinoethoxy or 2- pyridylmethyloxy, wherein the C _1-6 alkoxy, benzyloxy and 2-pyridylmethyloxy of R ¹⁰ are each optionally substituted with CN; (iv) when L ¹ is a bond, then not

H, methyl, (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ¹⁰ is H, methyl, CN, methoxy, cyclopropylmethoxy, benzyloxy, (2-cyanophenyl)methoxy, 2- pyridylmethoxy, 3-pyridylmethoxy, (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl; R ¹¹ is H, halo, methyl or dimethylamino; R ¹⁶ is H or methyl; each R ¹⁷ is independently H, 2-hydroxyethyl or carboxymethyl; R ¹⁸ is H or methyl; R ¹⁹ is (2- hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ²⁰ is C _1-6 alkyl; each R ²¹ is independently 2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; and R ²² is H or Cl; (vi) when L ¹ is–NH- and ⁽

phenyl, 2,3-dihydro-1,4-benzodioxin-6-yl,

cyclohexyl or 1-cyclohexenyl, then or herein each R ⁹ is independently (2-hydroxyethylamino)methyl or (2- carboxy-1-piperidinyl)methyl;

(vii) when L ¹ is–CH2O-, ring B is phenyl or thienyl, and the subscript n is 1 or 2, then R ⁵ is not a substituent independently selected from H, -OCH ₃ , -OH, -OCH ₂ CH ₃ , - O(CH2)OCH3, -OCH2CH=CH2, -O(CH2)2CH3, -O(CH2)2morpholinyl or F; and

(viii) when L ¹ is–CH ₂ O-, ring B is phenyl or thienyl, and the subscript n is 2, then two R ⁵ substituents attached to adjacent ring carbon atoms of ring B do not form–OCH2O- or–OCH ₂ CH ₂ O-; and

wherein the compound, or a pharmaceutically acceptable salt or a stereoisomer thereof inhibits PD-1/PD-L1 interaction.

In some embodiments, G has Formula (I’a) or (I’b): (

(I’a) (I’b)

In some embodiments,

when ring C is 4- to 14-membered heterocycloalkyl or C3-14 cycloalkyl,

R ⁴ is H, halo, oxo, CN, C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C _2-6 alkynyl, C _1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl, or C _3-6 cycloalkyl, wherein the C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C _2-6 alkynyl, 4- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl and C3-6 cycloalkyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl, phenyl, NH ₂ , -NHR ⁸ , -NR ⁸ R ⁸ , C(O)R ⁸ , C(O)NR ⁸ R ⁸ , OC(O)NR ⁸ R ⁸ , NR ⁸ C(O)R ⁸ , NR ⁸ C(O)OR ⁸ , NR ⁸ C(O)NR ⁸ R ⁸ , NR ⁸ S(O)2R ⁸ ,

NR ⁸ S(O) ₂ NR ⁸ R ⁸ , S(O)R ⁸ , S(O) ₂ R ⁸ , and S(O) ₂ NR ⁸ R ⁸ ,

wherein each R ⁸ is independently H or C1-6 alkyl.

In some embodiments, R ⁴ is halo, oxo, CN, C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, 5- to 6- membered heteroaryl, phenyl, or C _3-6 cycloalkyl, wherein the C _1-6 alkyl, C _1-6 alkoxy, C _2-6 alkenyl, C2-6 alkynyl, 4- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl and C _3-6 cycloalkyl are each optionally substituted with 1, 2 or 3 substituents

independently selected from halo, CN, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6- membered heterocycloalkyl, C _3-6 cycloalkyl, 5- to 6-membered heteroaryl, phenyl, NH ₂ , - NHR ⁸ , -NR ⁸ R ⁸ , C(O)R ⁸ , C(O)NR ⁸ R ⁸ , OC(O)NR ⁸ R ⁸ , NR ⁸ C(O)R ⁸ , NR ⁸ C(O)OR ⁸ ,

NR ⁸ C(O)NR ⁸ R ⁸ , NR ⁸ S(O) ₂ R ⁸ , NR ⁸ S(O) ₂ NR ⁸ R ⁸ , S(O)R ⁸ , S(O) ₂ R ⁸ , and S(O) ₂ NR ⁸ R ⁸ ;

wherein each R ⁸ is independently H or C1-6 alkyl.

In some embodiments of the compound of Formula (I’): G

(I’) 

or a pharmaceutically acceptable salt or a stereoisomer thereof,

G has Formula (I’a) or (I’b) (

(I’a) (I’b)

when G is of Formula (I’a), the atoms on ring C, to which the substituent R ⁴ and ring B are attached can be either carbon or nitrogen; and is a single bond or a double bond;

when G is of Formula (I’b), ring B and ring C are joined together through a quaternary ring carbon atom to form a spiro structure and ring B and ring C are each independently 4- to 14- membered heterocycloalkyl or C3-14 cycloalkyl;

L ¹ is a bond,–(CR ¹⁴ R ¹⁵ ) _t C(O)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)(CR ¹⁴ R ¹⁵ ) _t -, O, - (CR ¹⁴ R ¹⁵ )p-, -(CR ¹⁴ R ¹⁵ )p-O-, -O(CR ¹⁴ R ¹⁵ )p-, -(CR ¹⁴ R ¹⁵ )p-O-(CR ¹⁴ R ¹⁵ )p-, -NR ¹³ -, - _(CR ¹⁴ _R ¹⁵ ₎ ¹³

t _NR ¹³ _(CR ¹⁴ _R ¹⁵ _{)t -, -NH-, -(CR} ¹⁴ _R ¹⁵ _)tNH(CR ¹⁴ _R ¹⁵ _{)t-, -CR} ¹³ _{=CR -,} ^{C C} _{, -SO2-, -} (CR ¹⁴ R ¹⁵ ) _t SO ₂ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t SO ₂ NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -(CR ¹⁴ R ¹⁵ ) _t NR ¹³ SO ₂ (CR ¹⁴ R ¹⁵ ) _t -, - (CR ¹⁴ R ¹⁵ )tNR ¹³ SO2NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)O(CR ¹⁴ R ¹⁵ )t -, -NR ¹³ C(O)O-, - (CR ¹⁴ R ¹⁵ ) _t O(CO)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, -O(CO)NR ¹³ -,–NR ¹³ C(O)NR ¹³ - or - (CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)NR ¹³ (CR ¹⁴ R ¹⁵ )t;

ring A is C _6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C3-14 cycloalkyl;

ring B is C _6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C3-14 cycloalkyl;

ring C is C _6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C3-14 cycloalkyl;

each R ¹³ is independently H, C _1-6 haloalkyl or C _1-6 alkyl optionally substituted with a substituent selected from C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, halo, OH, - COOH, NH ₂ , -NHC _1-4 alkyl and–N(C _1-4 alkyl) ₂ ;

R ¹⁴ and R ¹⁵ are each independently selected from H, halo, CN, OH, -COOH, C1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ¹⁴ or R ¹⁵ are each optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

or R ¹⁴ and R ¹⁵ taken together with the carbon atom to which they are attached form C3-6 cycloalkyl or 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

R ⁴ is halo, oxo, CN, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C _1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl, or C3-6 cycloalkyl, wherein the C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 4- to 6- membered heterocycloalkyl, 5- to 6-membered heteroaryl, phenyl and C _3-6 cycloalkyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, C _1-6 alkoxy, C _1-6 haloalkyl, C _1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, C _3-6

cycloalkyl, 5- to 6-membered heteroaryl, phenyl, NH2, -NHR ⁸ , -NR ⁸ R ⁸ , C(O)R ⁸ ,

C(O)NR ⁸ R ⁸ , OC(O)NR ⁸ R ⁸ , NR ⁸ C(O)R ⁸ , NR ⁸ C(O)OR ⁸ , NR ⁸ C(O)NR ⁸ R ⁸ , NR ⁸ S(O) ₂ R ⁸ , NR ⁸ S(O)2NR ⁸ R ⁸ , S(O)R ⁸ , S(O)2R ⁸ , and S(O)2NR ⁸ R ⁸ , wherein each R ⁸ is independently H or C _1-6 alkyl;

R ⁵ , R ⁶ and R ³¹ are each independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered

heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO ₂ , OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NR ^a )NR ^a R ^a , NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O) ₂ R ^a , NR ^a S(O)2NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O)2R ^a , and S(O)2NR ^a R ^a , wherein the C1-6 alkyl, C2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ⁵ , R ⁶ and R ³¹ are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents; or two adjacent R ⁵ substituents on ring B, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6- membered heteroaryl ring and fused C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ⁵ substituents on the same ring carbon atom of ring B, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two adjacent R ⁶ substituents on ring A, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ⁶ substituents on the same ring carbon atom of the ring A, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two adjacent R ³¹ substituents on ring C, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ³¹ substituents on the same ring carbon atom of ring C, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

each R ^a is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^a are each optionally substituted with 1, 2 or 3 independently selected R ^d substituents; each R ^b substituent is independently selected from halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHOR ^c , OR ^c , SR ^c , C(O)R ^c , C(O)NR ^c R ^c , C(O)OR ^c , OC(O)R ^c , OC(O)NR ^c R ^c , C(=NR ^c )NR ^c R ^c , NR ^c C(=NR ^c )NR ^c R ^c , NR ^c C(=NOH)NR ^c R ^c , NR ^c C(=NCN)NR ^c R ^c , NHR ^c , NR ^c R ^c , NR ^c C(O)R ^c , NR ^c C(O)OR ^c , NR ^c C(O)NR ^c R ^c , NR ^c S(O)R ^c , NR ^c S(O)2R ^c ,

NR ^c S(O) ₂ NR ^c R ^c , S(O)R ^c , S(O)NR ^c R ^c , S(O) ₂ R ^c and S(O) ₂ NR ^c R ^c ; wherein the C _1-6 alkyl, C _2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^b are each further optionally substituted with 1, 2, or 3 independently selected R ^d substituents;

or two R ^b substituents attached to the same ring carbon atom taken together with the ring carbon atom to which they are attached form spiro C3-6 cycloalkyl or spiro 4- to 7- membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^f substituents;

each R ^c is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^c are each optionally substituted with 1, 2 or 3 independently selected R ^f substituents; each R ^f is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, halo, CN, NHOR ^g , OR ^g , SR ^g , C(O)R ^g , C(O)NR ^g R ^g , C(O)OR ^g , OC(O)R ^g , OC(O)NR ^g R ^g , NHR ^g , NR ^g R ^g , NR ^g C(O)R ^g , NR ^g C(O)NR ^g R ^g , NR ^g C(O)OR ^g , C(=NR ^g )NR ^g R ^g , NR ^g C(=NR ^g )NR ^g R ^g ,

NR ^g C(=NOH)NR ^g R ^g , NR ^g C(=NCN)NR ^g R ^g , S(O)R ^g , S(O)NR ^g R ^g , S(O)2R ^g , NR ^g S(O)2R ^g , NR ^g S(O) ₂ NR ^g R ^g , and S(O) ₂ NR ^g R ^g ; wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^f are each optionally substituted with 1, 2 or 3 independently selected R ⁿ substituents;

each R ⁿ is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NHOR ^o , OR ^o , SR ^o , C(O)R ^o , C(O)NR ^o R ^o , C(O)OR ^o , OC(O)R ^o , OC(O)NR ^o R ^o , NHR ^o , NR ^o R ^o , NR ^o C(O)R ^o , NR ^o C(O)NR ^o R ^o , NR ^o C(O)OR ^o , C(=NR ^o )NR ^o R ^o , NR ^o C(=NR ^o )NR ^o R ^o , S(O)R ^o , S(O)NR ^o R ^o , S(O)2R ^o , NR ^o S(O)2R ^o ,

NR ^o S(O) ₂ NR ^o R ^o , and S(O) ₂ NR ^o R ^o , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ⁿ is optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

each R ^d is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, C6-10 aryl, 5-10 membered heteroaryl, C _3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl- , C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, CN, NH ₂ , NHOR ^e , OR ^e , SR ^e , C(O)R ^e , C(O)NR ^e R ^e , C(O)OR ^e , OC(O)R ^e , OC(O)NR ^e R ^e , NHR ^e , NR ^e R ^e , NR ^e C(O)R ^e , NR ^e C(O)NR ^e R ^e , NR ^e C(O)OR ^e , C(=NR ^e )NR ^e R ^e , NR ^e C(=NR ^e )NR ^e R ^e , NR ^e C(=NOH)NR ^e R ^e , NR ^e C(=NCN)NR ^e R ^e , S(O)R ^e , S(O)NR ^e R ^e , S(O)2R ^e , NR ^e S(O)2R ^e , NR ^e S(O)2NR ^e R ^e , and S(O)2NR ^e R ^e , wherein the C1-6 alkyl, C1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^d are each optionally substituted with 1, 2, or3 independently selected R ^f substituents;

each R ^e is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, wherein the C _1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^e are each optionally substituted with 1, 2 or 3 independently selected R ^f substituents;

each R ^g is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, wherein the C _1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^g are each optionally substituted with 1, 2, or 3 independently selected R ^p substituents;

each R ^p is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, halo, CN, NHOR ^r , OR ^r , SR ^r , C(O)R ^r , C(O)NR ^r R ^r , C(O)OR ^r , OC(O)R ^r , OC(O)NR ^r R ^r , NHR ^r , NR ^r R ^r , NR ^r C(O)R ^r , NR ^r C(O)NR ^r R ^r , NR ^r C(O)OR ^r , C(=NR ^r )NR ^r R ^r , NR ^r C(=NR ^r )NR ^r R ^r , NR ^r C(=NOH)NR ^r R ^r , NR ^r C(=NCN)NR ^r R ^r , S(O)R ^r , S(O)NR ^r R ^r , S(O)2R ^r , NR ^r S(O)2R ^r , NR ^r S(O)2NR ^r R ^r and S(O) ₂ NR ^r R ^r , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^p is optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or any two R ^a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 independently selected R ^h substituents;

each R ^h is independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- ₁₀ cycloalkyl, 4-10 membered heterocycloalkyl, C _6-10 aryl, 5-10 membered heteroaryl, C _3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered

heterocycloalkyl)-C _1-4 alkyl-, C _6-10 aryl-C _1-4 alkyl-, C _2-6 alkenyl, C _2-6 alkynyl, halo, CN, OR ⁱ , SR ⁱ , NHOR ⁱ , C(O)R ⁱ , C(O)NR ⁱ R ⁱ , C(O)OR ⁱ , OC(O)R ⁱ , OC(O)NR ⁱ R ⁱ , NHR ⁱ , NR ⁱ R ⁱ ,

NR ⁱ C(O)R ⁱ , NR ⁱ C(O)NR ⁱ R ⁱ , NR ⁱ C(O)OR ⁱ , C(=NR ⁱ )NR ⁱ R ⁱ , NR ⁱ C(=NR ⁱ )NR ⁱ R ⁱ ,

NR ⁱ C(=NOH)NR ⁱ R ⁱ , NR ⁱ C(=NCN)NR ⁱ R ⁱ , S(O)R ⁱ , S(O)NR ⁱ R ⁱ , S(O)2R ⁱ , NR ⁱ S(O)2R ⁱ , NR ⁱ S(O) ₂ NR ⁱ R ⁱ , and S(O) ₂ NR ⁱ R ⁱ , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _1-6 haloalkoxy, C _3- 10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4- 10 membered heterocycloalkyl)-C1-4 alkyl- of R ^h are each optionally substituted by 1, 2, or 3 independently selected R ^j substituents;

each R ^j is independently selected from C1-4 alkyl, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _2-4 alkenyl, C _2-4 alkynyl, halo, C _1-4 haloalkyl, C1-4 haloalkoxy, CN, NHOR ^k , OR ^k , SR ^k , C(O)R ^k , C(O)NR ^k R ^k , C(O)OR ^k , OC(O)R ^k , OC(O)NR ^k R ^k , NHR ^k , NR ^k R ^k , NR ^k C(O)R ^k , NR ^k C(O)NR ^k R ^k , NR ^k C(O)OR ^k , C(=NR ^k )NR ^k R ^k , NR ^k C(=NR ^k )NR ^k R ^k , S(O)R ^k , S(O)NR ^k R ^k , S(O) ₂ R ^k , NR ^k S(O) ₂ R ^k , NR ^k S(O)2NR ^k R ^k , and S(O)2NR ^k R ^k , wherein the C1-4 alkyl, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _2-4 alkenyl, C _1-4 haloalkyl, and C _1-4 haloalkoxy of R ^j are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or two R ^h groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C _3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;

or any two R ^c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ⁱ substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^o substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents; and

or any two R ^r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

each R ⁱ , R ^k , R ^o or R ^r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C _6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C _1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C2-4 alkenyl, and C2-4 alkynyl of R ⁱ , R ^k , R ^o or R ^r are each optionally substituted with 1, 2 or 3 R ^q substituents;

each R ^q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C _1-6 alkyl, C _1-6 alkoxy, C _1-6 haloalkoxy, C _1-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR ¹² and NR ¹² R ¹² , wherein the C1-6 alkyl, phenyl, C _3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R ^q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C _1-4 haloalkoxy, phenyl, C _3-10 cycloalkyl, 5- or 6-membered heteroaryl and 4-6 membered heterocycloalkyl and each R ¹² is independently C1-6 alkyl;

the subscript n is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

the subscript m is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

each subscript p is independently an integer of 1, 2, 3 or 4;

each subscript t is independently an integer of 0, 1, 2, 3 or 4;

the subscript u is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

with the provisos:

wherein each R ⁹ is independently (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl and each R ¹¹ is independently H, halo, CN, C1-6 alkyl, C1-6 alkoxy, - NHC _1-6 alkyl or benzyloxy, wherein the C _1-6 alkyl, C _1-6 alkoxy, -NHC _1-6 alkyl and benzyloxy of R ¹¹ are each optionally substituted with halo, CN, C1-6 alkyl or C1-6 alkoxy; -

independently (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; each R ¹¹ is independently H or C1-6 alkyl and R ¹⁰ is H, C1-6 alkoxy, benzyloxy, morpholinoethoxy or 2- pyridylmethyloxy, wherein the C _1-6 alkoxy, benzyloxy and 2-pyridylmethyloxy of R ¹⁰ are each o tionall substituted with CN

herein each R ⁹ is independently H, methyl, (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ¹⁰ is H, methyl, CN, methoxy, cyclopropylmethoxy, benzyloxy, (2-cyanophenyl)methoxy, 2- pyridylmethoxy, 3-pyridylmethoxy, (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl; R ¹¹ is H, halo, methyl or dimethylamino; R ¹⁶ is H or methyl; each R ¹⁷ is independently H, 2-hydroxyethyl or carboxymethyl; R ¹⁸ is H or methyl; R ¹⁹ is (2- hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ²⁰ is C _1-6 alkyl; each R ²¹ is independently 2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; and R ²² is H or Cl;

carboxy-1-piperidinyl)methyl; (vii) when L ¹ is–CH2O-, ring B is phenyl or thienyl, and the subscript n is 1 or 2, then R ⁵ is not a substituent independently selected from H, -OCH ₃ , -OH, -OCH ₂ CH ₃ , - O(CH2)OCH3, -OCH2CH=CH2, -O(CH2)2CH3, -O(CH2)2morpholinyl or F; and

(viii) when L ¹ is–CH ₂ O-, ring B is phenyl or thienyl, and the subscript n is 2, then two R ⁵ substituents attached to adjacent ring carbon atoms of ring B do not form–OCH2O- or–OCH ₂ CH ₂ O-; and

wherein the compound, or a pharmaceutically acceptable salt or a stereoisomer thereof inhibits PD-1/PD-L1 interaction. In some embodiments, the present disclosure provides a compound of Formula (I’c): (

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

ring D is C6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered heterocycloalkyl or C3-14 cycloalkyl;

L ² is a bond,–(CR ²⁹ R ³⁰ )tC(O)NR ²⁸ (CR ²⁹ R ³⁰ )t-, -(CR ²⁹ R ³⁰ )tNR ²⁸ C(O)(CR ²⁹ R ³⁰ )t -, O, - (CR ²⁹ R ³⁰ ) _q -, -(CR ²⁹ R ³⁰ ) _q -O-, -O(CR ²⁹ R ³⁰ ) _q -, -(CR ²⁹ R ³⁰ ) _q -O-(CR ²⁹ R ³⁰ ) _q -, -NR ²⁸ -, - _(CR ²⁹ _R ³⁰ _)wNR ²⁸ _(CR ²⁹ _R ³⁰ _{)w-, -NH-, -(CR} ²⁹ _R ³⁰ _)wNH(CR ²⁹ _R ³⁰ _{)w-, -CR} ²⁸ _=CR ²⁸ _-, ^{C C} _{, -SO2-,} -(CR ²⁹ R ³⁰ )wSO2(CR ²⁹ R ³⁰ )w-, -(CR ²⁹ R ³⁰ )wSO2NR ²⁸ (CR ²⁹ R ³⁰ )w-, -(CR ²⁹ R ³⁰ )wNR ²⁸ SO2(CR ²⁹ R ³⁰ )w- , -(CR ²⁹ R ³⁰ ) _w NR ²⁸ SO ₂ NR ²⁸ (CR ²⁹ R ³⁰ ) _w -, -(CR ²⁹ R ³⁰ ) _w NR ²⁸ C(O)O(CR ²⁹ R ³⁰ ) _w -, -NR ²⁸ C(O)O-, - (CR ²⁹ R ³⁰ )wO(CO)NR ²⁸ (CR ²⁹ R ³⁰ )w-, -O(CO)NR ²⁸ -,–NR ²⁸ C(O)NR ²⁸ - or - (CR ²⁹ R ³⁰ ) _w NR ²⁸ C(O)NR ²⁸ (CR ²⁹ R ³⁰ ) _w ;

each R ²⁸ is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, CN, halo, OH, - COOH, NH2, -NHC1-4 alkyl and–N(C1-4 alkyl)2;

R ²⁹ and R ³⁰ are each independently selected from H, halo, CN, OH, -COOH, C _1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, C _3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ²⁹ or R ³⁰ are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents; or R ²⁹ and R ³⁰ taken together with the carbon atom to which they are attached form C3-6 cycloalkyl or 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

each R ³² is independently selected from halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a , NR ^a C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O) ₂ R ^a , NR ^a S(O) ₂ NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O)2R ^a , and S(O)2NR ^a R ^a , wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1- 4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ³² are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents;

or two adjacent R ³² substituents on ring B, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6- membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C3-6 cycloalkyl ring are each

optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

the subscript n is an integer of 0, 1, 2, 3, 4, 5;

the subscript v is an integer of 0, 1, 2, 3, 4, 5, 6 or 7

each subscript q is independently an integer of 1, 2, 3 or 4;

each subscript t is independently an integer of 0, 1, 2, 3 or 4; and

each subscript w is independently an integer of 0, 1, 2, 3 or 4. In some embodiments the resent disclosure rovides a com ound of Formula I’d):

(

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

ring B and ring C are each independently 4- to 14-membered heterocycloalkyl or C _3-14 cycloalkyl;

ring D is C _6-10 aryl, 5- to 14-membered heteroaryl, 4- to 14-membered

heterocycloalkyl or C3-14 cycloalkyl;

L ² is a bond,–(CR ²⁹ R ³⁰ ) _t C(O)NR ²⁸ (CR ²⁹ R ³⁰ ) _t -, -(CR ²⁹ R ³⁰ ) _t NR ²⁸ C(O)(CR ²⁹ R ³⁰ ) _t -, O, - (CR ²⁹ R ³⁰ )q-, -(CR ²⁹ R ³⁰ )q-O-, -O(CR ²⁹ R ³⁰ )q-, -(CR ²⁹ R ³⁰ )q-O-(CR ²⁹ R ³⁰ )q-, -NR ²⁸ -, - _(CR ²⁹ _R ³⁰ _)wNR ²⁸ _(CR ²⁹ _R ³⁰ _{)w-, -NH-, -(CR} ²⁹ _R ³⁰ _)wNH(CR ²⁹ _R ³⁰ _{)w-, -CR} ²⁸ _=CR ²⁸ _-, ^{C C} _{, -SO2-,} -(CR ²⁹ R ³⁰ )wSO2(CR ²⁹ R ³⁰ )w-, -(CR ²⁹ R ³⁰ )wSO2NR ²⁸ (CR ²⁹ R ³⁰ )w-, -(CR ²⁹ R ³⁰ )wNR ²⁸ SO2(CR ²⁹ R ³⁰ )w- , -(CR ²⁹ R ³⁰ ) _w NR ²⁸ SO ₂ NR ²⁸ (CR ²⁹ R ³⁰ ) _w -, -(CR ²⁹ R ³⁰ ) _w NR ²⁸ C(O)O(CR ²⁹ R ³⁰ ) _w -, -NR ²⁸ C(O)O-, - (CR ²⁹ R ³⁰ )wO(CO)NR ²⁸ (CR ²⁹ R ³⁰ )w-, -O(CO)NR ²⁸ -,–NR ²⁸ C(O)NR ²⁸ - or - (CR ²⁹ R ³⁰ ) _w NR ²⁸ C(O)NR ²⁸ (CR ²⁹ R ³⁰ ) _w ;

each R ²⁸ is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, CN, halo, OH, - COOH, NH2, -NHC1-4 alkyl and–N(C1-4 alkyl)2;

R ²⁹ and R ³⁰ are each independently selected from H, halo, CN, OH, NH ₂ , -COOH, C _1- 4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ²⁹ or R ³⁰ are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or R ²⁹ and R ³⁰ taken together with the carbon atom to which they are attached form spiro C3-6 cycloalkyl or spiro 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

each R ³² is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C _1-6 haloalkoxy, C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a , NR ^a C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O) ₂ R ^a , NR ^a S(O) ₂ NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O)2R ^a , and S(O)2NR ^a R ^a , wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1- 4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ³² are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents;

or two adjacent R ³² substituents on ring B, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ³² substituents on the same ring carbon atom of ring B, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered

heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

the subscript n is an integer of 0, 1, 2, 3, 4, 5;

the subscript v is an integer of 0, 1, 2, 3, 4, 5, 6 or 7

each subscript q is independently an integer of 1, 2, 3 or 4;

each subscript t is independently an integer of 0, 1, 2, 3 or 4; and

each subscript w is independently an integer of 0, 1, 2, 3 or 4. In some embodiments the present disclosure provides a compound of Formula (I):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

Z ¹ is N or CR ¹ ;

Z ² is N or CR ² ;

Z ³ is N or CR ³ ; L ¹ is a bond,–(CR ¹⁴ R ¹⁵ )tC(O)NR ¹³ (CR ¹⁴ R ¹⁵ )t-, -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)(CR ¹⁴ R ¹⁵ )t -, O, - (CR ¹⁴ R ¹⁵ ) _p -, -(CR ¹⁴ R ¹⁵ ) _p -O-, -O(CR ¹⁴ R ¹⁵ ) _p -, -(CR ¹⁴ R ¹⁵ ) _p -O-(CR ¹⁴ R ¹⁵ ) _p -, -NR ¹³ -, - _(CR ¹⁴ _R ¹⁵ _)tNR ¹³ _(CR ¹⁴ _R ¹⁵ _{)t -, -NH-, -(CR} ¹⁴ _R ¹⁵ _)tNH(CR ¹⁴ _R ¹⁵ _{)t-, -CR} ¹³ _=CR ¹³ _-, ^{C C} _{, -SO2-, -} (CR ¹⁴ R ¹⁵ )tSO2(CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tSO2NR ¹³ (CR ¹⁴ R ¹⁵ )t -, -(CR ¹⁴ R ¹⁵ )tNR ¹³ SO2(CR ¹⁴ R ¹⁵ )t -, - (CR ¹⁴ R ¹⁵ ) _t NR ¹³ C(O)O(CR ¹⁴ R ¹⁵ ) _t -, -NR ¹³ C(O)O-, -(CR ¹⁴ R ¹⁵ ) _t O(CO)NR ¹³ (CR ¹⁴ R ¹⁵ ) _t -, - O(CO)NR ¹³ -,–NR ¹³ C(O)NR ¹³ - or -(CR ¹⁴ R ¹⁵ )tNR ¹³ C(O)NR ¹³ (CR ¹⁴ R ¹⁵ )t;

ring A is C _6-10 aryl, 5- to 14-membered heteroaryl, 4- to 11-membered

heterocycloalkyl or C3-10 cycloalkyl;

ring B is C6-10 aryl, 5- to 14-membered heteroaryl, 4- to 11-membered

heterocycloalkyl or C _3-10 cycloalkyl;

each R ¹³ is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, CN, halo, OH, - COOH, NH2, -NHC1-4 alkyl and–N(C1-4 alkyl)2;

R ¹⁴ and R ¹⁵ are each independently selected from H, halo, CN, OH, -COOH, C _1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ¹⁴ or R ¹⁵ are each optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

or R ¹⁴ and R ¹⁵ taken together with the carbon atom to which they are attached form spiro C3-6 cycloalkyl or spiro 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

R ¹ , R ² and R ³ are each independently selected from H, C1-4 alkyl, C3-10 cycloalkyl, C3- ₁₀ cycloalkyl-C _1-4 alkyl-, C _6-10 aryl, C _6-10 aryl-C _1-4 alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, C _2-4 alkenyl, C _2-4 alkynyl, halo, CN, OR ⁷ , C _1-4 haloalkyl, C _1-4 haloalkoxy, NH2, -NHR ⁷ , -NR ⁷ R ⁷ , NHOR ⁷ , C(O)R ⁷ , C(O)NR ⁷ R ⁷ , C(O)OR ⁷ , OC(O)R ⁷ , OC(O)NR ⁷ R ⁷ , NR ⁷ C(O)R ⁷ , NR ⁷ C(O)OR ⁷ , NR ⁷ C(O)NR ⁷ R ⁷ , C(=NR ⁷ )R ⁷ , C(=NR ⁷ )NR ⁷ R ⁷ , NR ⁷ C(=NR ⁷ )NR ⁷ R ⁷ , NR ⁷ S(O)R ⁷ , NR ⁷ S(O) ₂ R ⁷ , NR ⁷ S(O) ₂ NR ⁷ R ⁷ , S(O)R ⁷ , S(O)NR ⁷ R ⁷ , S(O)2R ⁷ , and S(O)2NR ⁷ R ⁷ , wherein each R ⁷ is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-10 cycloalkyl-C _1-4 alkyl-, C _6-10 aryl, C _6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10

membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, wherein the C1-4 alkyl, C1-4 alkoxy, C3-10 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C6-10 aryl, C6-10 aryl-C1- ₄ alkyl-, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ¹ , R ² , R ³ and R ⁷ are each optionally substituted with 1 or 2 independently selected R ^d substituents;

R ⁴ is halo, CN, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl or C _3-6 cycloalkyl, wherein the C _1-6 alkyl, C _1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 4 to 6-membered heterocycloalkyl and C3-6 cycloalkyl are each optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, 4 to 6-membered heterocycloalkyl, C3-6 cycloalkyl, phenyl, NH ₂ , -NHR ⁸ , -NR ⁸ R ⁸ , C(O)R ⁸ , C(O)NR ⁸ R ⁸ , OC(O)NR ⁸ R ⁸ , NR ⁸ C(O)R ⁸ , NR ⁸ C(O)OR ⁸ , NR ⁸ C(O)NR ⁸ R ⁸ , NR ⁸ S(O)2R ⁸ , NR ⁸ S(O)2NR ⁸ R ⁸ , S(O)R ⁸ , S(O)2R ⁸ , and S(O) ₂ NR ⁸ R ⁸ , wherein each R ⁸ is independently H or C _1-6 alkyl;

R ⁵ and R ⁶ are each independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO ₂ , OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NR ^a )NR ^a R ^a , NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O) ₂ R ^a , NR ^a S(O)2NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O)2R ^a , and S(O)2NR ^a R ^a , wherein the C1-6 alkyl, C2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ⁵ and R ⁶ are each optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents;

or two adjacent R ⁵ substituents on ring B, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ⁵ substituents on the same ring carbon atom of ring B, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two adjacent R ⁶ substituents on ring A, taken together with the atoms to which they are attached, form a fused phenyl ring, a fused 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused 5-, 6- or 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

or two R ⁶ substituents on the same ring carbon atom of the ring A, taken together with the carbon atom to which they are attached, form a spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a spiro C3-6 cycloalkyl ring, wherein the spiro 4-, 5-, 6- or 7- membered heterocycloalkyl ring has 1-4 heteroatoms as ring members selected from N, O and S and wherein the spiro 4-, 5-, 6- or 7-membered heterocycloalkyl ring and spiro C3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 independently selected R ^b substituents;

each R ^a is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^a are each optionally substituted with 1, 2 or 3 independently selected R ^d substituents; each R ^b substituent is independently selected from halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, OH, NH2, NO2, NHOR ^c , OR ^c , SR ^c , C(O)R ^c , C(O)NR ^c R ^c , C(O)OR ^c , OC(O)R ^c , OC(O)NR ^c R ^c , C(=NR ^c )NR ^c R ^c , NR ^c C(=NR ^c )NR ^c R ^c , NR ^c C(=NOH)NR ^c R ^c , NR ^c C(=NCN)NR ^c R ^c , NHR ^c , NR ^c R ^c , NR ^c C(O)R ^c , NR ^c C(O)OR ^c , NR ^c C(O)NR ^c R ^c , NR ^c S(O)R ^c , NR ^c S(O)2R ^c ,

NR ^c S(O) ₂ NR ^c R ^c , S(O)R ^c , S(O)NR ^c R ^c , S(O) ₂ R ^c and S(O) ₂ NR ^c R ^c ; wherein the C _1-6 alkyl, C _2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^b are each further optionally substituted with 1, 2, or 3 independently selected R ^d substituents;

or two R ^b substituents attached to the same ring carbon atom taken together with the ring carbon atom to which they are attached form spiro C3-6 cycloalkyl or spiro 4- to 7- membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^f substituents;

each R ^c is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl- , (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^c are each optionally substituted with 1, 2 or 3 R ^f substituents;

each R ^f is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, halo, CN, NHOR ^g , OR ^g , SR ^g , C(O)R ^g , C(O)NR ^g R ^g , C(O)OR ^g , OC(O)R ^g , OC(O)NR ^g R ^g , NHR ^g , NR ^g R ^g , NR ^g C(O)R ^g , NR ^g C(O)NR ^g R ^g , NR ^g C(O)OR ^g , C(=NR ^g )NR ^g R ^g , NR ^g C(=NR ^g )NR ^g R ^g ,

NR ^g C(=NOH)NR ^g R ^g , NR ^g C(=NCN)NR ^g R ^g , S(O)R ^g , S(O)NR ^g R ^g , S(O)2R ^g , NR ^g S(O)2R ^g , NR ^g S(O) ₂ NR ^g R ^g , and S(O) ₂ NR ^g R ^g ; wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^f are each optionally substituted with 1, 2 or 3 R ⁿ substituents;

each R ⁿ is independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, NHOR ^o , OR ^o , SR ^o , C(O)R ^o , C(O)NR ^o R ^o , C(O)OR ^o , OC(O)R ^o , OC(O)NR ^o R ^o , NHR ^o , NR ^o R ^o , NR ^o C(O)R ^o , NR ^o C(O)NR ^o R ^o , NR ^o C(O)OR ^o , C(=NR ^o )NR ^o R ^o , NR ^o C(=NR ^o )NR ^o R ^o , S(O)R ^o , S(O)NR ^o R ^o , S(O)2R ^o , NR ^o S(O)2R ^o ,

NR ^o S(O) ₂ NR ^o R ^o , and S(O) ₂ NR ^o R ^o , wherein the C _1-6 alkyl, C _1-6 haloalkyl, phenyl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ⁿ is optionally substituted with 1, 2 or 3 R ^q substituents; each R ^d is independently selected from C _1-6 alkyl, C _1-6 haloalkyl, halo, C _6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NH2, NHOR ^e , OR ^e , SR ^e , C(O)R ^e , C(O)NR ^e R ^e , C(O)OR ^e , OC(O)R ^e , OC(O)NR ^e R ^e , NHR ^e , NR ^e R ^e , NR ^e C(O)R ^e , NR ^e C(O)NR ^e R ^e , NR ^e C(O)OR ^e , C(=NR ^e )NR ^e R ^e , NR ^e C(=NR ^e )NR ^e R ^e , NR ^e C(=NOH)NR ^e R ^e , NR ^e C(=NCN)NR ^e R ^e , S(O)R ^e , S(O)NR ^e R ^e , S(O)2R ^e , NR ^e S(O)2R ^e , NR ^e S(O)2NR ^e R ^e , and S(O)2NR ^e R ^e , wherein the C1-6 alkyl, C1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^d are each optionally substituted with 1, 2, or3 independently selected R ^f substituents;

each R ^e is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl- , (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ^e are each optionally substituted with 1, 2 or 3 independently selected R ^f substituents;

each R ^g is independently selected from H, C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein the C1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^g are each optionally substituted with 1, 2, or 3 R ^p substituents; each R ^p is independently selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered

heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl-, (4-10 membered heterocycloalkyl)-C _1-4 alkyl-, halo, CN, NHOR ^r , OR ^r , SR ^r , C(O)R ^r , C(O)NR ^r R ^r , C(O)OR ^r , OC(O)R ^r , OC(O)NR ^r R ^r , NHR ^r , NR ^r R ^r , NR ^r C(O)R ^r , NR ^r C(O)NR ^r R ^r , NR ^r C(O)OR ^r , C(=NR ^r )NR ^r R ^r , NR ^r C(=NR ^r )NR ^r R ^r , NR ^r C(=NOH)NR ^r R ^r , NR ^r C(=NCN)NR ^r R ^r , S(O)R ^r , S(O)NR ^r R ^r , S(O)2R ^r , NR ^r S(O)2R ^r , NR ^r S(O)2NR ^r R ^r and S(O) ₂ NR ^r R ^r , wherein the C _1-6 alkyl, C _1-6 haloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl- , C _3-10 cycloalkyl-C _1-4 alkyl-, (5-10 membered heteroaryl)-C _1-4 alkyl- and (4-10 membered heterocycloalkyl)-C1-4 alkyl- of R ^p is optionally substituted with 1, 2 or 3 R ^q substituents; or any two R ^a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R ^h substituents;

each R ^h is independently selected from C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- 10 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C3-10 cycloalkyl-C _1-4 alkyl-, (5-6 membered heteroaryl)-C _1-4 alkyl-, (4-7 membered

heterocycloalkyl)-C1-4 alkyl-, C6-10 aryl-C1-4 alkyl-, C2-6 alkenyl, C2-6 alkynyl, halo, CN, OR ⁱ , SR ⁱ , NHOR ⁱ , C(O)R ⁱ , C(O)NR ⁱ R ⁱ , C(O)OR ⁱ , OC(O)R ⁱ , OC(O)NR ⁱ R ⁱ , NHR ⁱ , NR ⁱ R ⁱ ,

NR ⁱ C(O)R ⁱ , NR ⁱ C(O)NR ⁱ R ⁱ , NR ⁱ C(O)OR ⁱ , C(=NR ⁱ )NR ⁱ R ⁱ , NR ⁱ C(=NR ⁱ )NR ⁱ R ⁱ ,

NR ⁱ C(=NOH)NR ⁱ R ⁱ , NR ⁱ C(=NCN)NR ⁱ R ⁱ , S(O)R ⁱ , S(O)NR ⁱ R ⁱ , S(O) ₂ R ⁱ , NR ⁱ S(O) ₂ R ⁱ , NR ⁱ S(O)2NR ⁱ R ⁱ , and S(O)2NR ⁱ R ⁱ , wherein the C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C3- ₁₀ cycloalkyl, 4-7 membered heterocycloalkyl, C _6-10 aryl, 5-6 membered heteroaryl, C _6-10 aryl- C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C _1-4 alkyl- of R ^h are each optionally substituted by 1, 2, or 3 R ^j substituents;

each R ^j is independently selected from C _1-4 alkyl, C _3-6 cycloalkyl, C _6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C2-4 alkynyl, halo, C1-4 haloalkyl, C _1-4 haloalkoxy, CN, NHOR ^k , OR ^k , SR ^k , C(O)R ^k , C(O)NR ^k R ^k , C(O)OR ^k , OC(O)R ^k , OC(O)NR ^k R ^k , NHR ^k , NR ^k R ^k , NR ^k C(O)R ^k , NR ^k C(O)NR ^k R ^k , NR ^k C(O)OR ^k , C(=NR ^k )NR ^k R ^k , NR ^k C(=NR ^k )NR ^k R ^k , S(O)R ^k , S(O)NR ^k R ^k , S(O) ₂ R ^k , NR ^k S(O) ₂ R ^k ,

NR ^k S(O)2NR ^k R ^k , and S(O)2NR ^k R ^k , wherein the C1-4 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5- or 6- membered heteroaryl, 4-6 membered heterocycloalkyl, C2-4 alkenyl, C1-4 haloalkyl, and C1-4 haloalkoxy of R ^j are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or two R ^h groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl, taken together with the carbon atom to which they are attached, form a C _3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;

or any two R ^c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ⁱ substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

or any two R ^o substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents; and

or any two R ^r substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^h substituents;

each R ⁱ , R ^k , R ^o or R ^r is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C _6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C _1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, C _6-10 aryl, 4-6 membered heterocycloalkyl, 5 or 6-membered heteroaryl, C _2-4 alkenyl, and C2-4 alkynyl of R ⁱ , R ^k , R ^o or R ^r are each optionally substituted with 1, 2 or 3 R ^q substituents; each R ^q is independently selected from OH, CN, -COOH, NH2, halo, C1-6 haloalkyl, C _1-6 alkyl, C _1-6 alkoxy, C _1-6 haloalkoxy, C _1-6 alkylthio, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, C3-6 cycloalkyl, NHR ¹² and NR ¹² R ¹² , wherein the C1-6 alkyl, phenyl, C _3-6 cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl of R ^q are each optionally substituted with halo, OH, CN, -COOH, NH2, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C _1-4 haloalkoxy, phenyl, C _3-10 cycloalkyl and 4-6 membered heterocycloalkyl and each R ¹² is independently C1-6 alkyl;

the subscript n is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

the subscript m is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8;

each subscript p is independently an integer of 1, 2, 3 or 4;

each subscript t is independently an integer of 0, 1, 2, 3 or 4;

with the provisos:

wherein each R ⁹ is independently (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl and each R ¹¹ is independently H, halo, CN, C _1-6 alkyl, C _1-6 alkoxy, - NHC1-6 alkyl or benzyloxy, wherein the C1-6 alkyl, C1-6 alkoxy, -NHC1-6 alkyl and benzyloxy of R ¹¹ are each optionally substituted with halo, CN, C _1-6 alkyl or C _1-6 alkoxy; -

independently (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; each R ¹¹ is independently H or C1-6 alkyl and R ¹⁰ is H, C1-6 alkoxy, benzyloxy, morpholinoethoxy or 2- pyridylmethyloxy, wherein the C _1-6 alkoxy, benzyloxy and 2-pyridylmethyloxy of R ¹⁰ are each o tionall substituted with CN

herein each R ⁹ is independently H, methyl, (2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ¹⁰ is H, methyl, CN, methoxy, cyclopropylmethoxy, benzyloxy, (2-cyanophenyl)methoxy, 2- pyridylmethoxy, 3-pyridylmethoxy, (2-hydroxyethylamino)methyl or (2-carboxy-1- piperidinyl)methyl; R ¹¹ is H, halo, methyl or dimethylamino; R ¹⁶ is H or methyl; each R ¹⁷ is independently H, 2-hydroxyethyl or carboxymethyl; R ¹⁸ is H or methyl; R ¹⁹ is (2- hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; R ²⁰ is C _1-6 alkyl; each R ²¹ is independently 2-hydroxyethylamino)methyl or (2-carboxy-1-piperidinyl)methyl; and R ²² is H or Cl; (vi) when L ¹ is–NH- a phenyl, 2,3-dihydro-1,4-benzodioxin-6-yl,

carboxy-1-piperidinyl)methyl; (vii) when L ¹ is–CH2O-, ring B is phenyl or thienyl, and the subscript n is 1 or 2, then R ⁵ is not a substituent independently selected from H, -OCH ₃ , -OH, -OCH ₂ CH ₃ , - O(CH2)OCH3, -OCH2CH=CH2, -O(CH2)2CH3, -O(CH2)2morpholinyl or F; and

(viii) when L ¹ is–CH ₂ O-, ring B is phenyl or thienyl, and the subscript n is 2, then two R ⁵ substituents attached to adjacent ring carbon atoms of ring B do not form–OCH2O- or–OCH ₂ CH ₂ O-; and

wherein the compound, or a pharmaceutically acceptable salt or a stereoisomer thereof inhibits PD-1/PD-L1 interaction.

In some embodiments, any two R ⁱ substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

or any two R ^k substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R ^q substituents.

In some embodiments, provided herein is a compound or a pharmaceutically acceptable salt or a stereoisomer thereof, having an IC50 of less than 1 µM in a PD-L1 binding assay. In some embodiments, the compounds as disclosed herein have an IC ₅₀ of less than 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 0.005, 0.004, 0.003, 0.002, or 0.001 µM. For example, the PD-L1 binding assay can be a PD-1/PD-L1 Homogeneous Time- Resolved Fluorescence (HTRF) binding assay as described in Example A. In some embodiments, the subscript m is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8 and the subscript n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8; or the subscript m is an integer of 1, 2, 3, 4, 5, 6, 7 or 8 and the subscript n is an integer of 0, 1, 2, 3, 4, 5, 6, 7 or 8; or the subscripts m and n are each independently an integer of 1, 2, 3, 4, 5, 6, 7 or 8.

I

In some embodiments, provided herein is a compound having Formula (II):

  R

(II) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

L ² is a bond,–(CR ²⁹ R ³⁰ ) _t C(O)NR ²⁸ (CR ²⁹ R ³⁰ ) _t -, -(CR ²⁹ R ³⁰ ) _t NR ²⁸ C(O)(CR ²⁹ R ³⁰ ) _t -, O, - (CR ²⁹ R ³⁰ )q-, -(CR ²⁹ R ³⁰ )q-O-, -O(CR ²⁹ R ³⁰ )q-, -(CR ²⁹ R ³⁰ )q-O-(CR ²⁹ R ³⁰ )q-, -NR ²⁸ -, - _(CR ²⁹ _R ³⁰ _)tNR ²⁸ _(CR ²⁹ _R ³⁰ _{)t -, -NH-, -(CR} ²⁹ _R ³⁰ _)tNH(CR ²⁹ _R ³⁰ _{)t-, -CH=CH-,} ^{C C} _{, -SO2-, -} (CR ²⁹ R ³⁰ ) _t SO ₂ (CR ²⁹ R ³⁰ ) _t -, -(CR ²⁹ R ³⁰ ) _t SO ₂ NR ²⁸ (CR ²⁹ R ³⁰ ) _t -, -(CR ²⁹ R ³⁰ ) _t NR ²⁸ SO ₂ (CR ²⁹ R ³⁰ ) _t -, - (CR ²⁹ R ³⁰ )tNR ²⁸ C(O)O(CR ²⁹ R ³⁰ )t -, -NR ²⁸ C(O)O-, -(CR ²⁹ R ³⁰ )tO(CO)NR ²⁸ (CR ²⁹ R ³⁰ )t -, - O(CO)NR ²⁸ -,–NR ²⁸ C(O)NR ²⁸ - or -(CR ²⁹ R ³⁰ ) _t NR ²⁸ C(O)NR ²⁸ (CR ²⁹ R ³⁰ ) _t ;

each R ²³ is independently C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, CN, halo, OH, -COOH, NH2, -NHC1-4 alkyl or–N(C1-4 alkyl)2;

R ²⁷ is C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-11 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents;

each R ²⁸ is independently H, C1-6 haloalkyl or C1-6 alkyl optionally substituted with a substituent selected from C _1-4 alkyl, C _1-4 alkoxy, C _1-4 haloalkyl, C _1-4 haloalkoxy, CN, halo, OH, - COOH, NH2, -NHC1-4 alkyl and–N(C1-4 alkyl)2;

R ²⁹ and R ³⁰ are each independently selected from H, halo, CN, OH, -COOH, C _1-4 alkyl, C1-4 alkoxy, -NHC1-4 alkyl, -N(C1-4 alkyl)2, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl of R ²⁹ or R ³⁰ are each optionally substituted with 1, 2 or 3 independently selected R ^q substituents;

or R ²⁹ and R ³⁰ taken together with the carbon atom to which they are attached form spiro C3-6 cycloalkyl or spiro 4- to 7-membered heterocycloalkyl, each of which is optionally substituted with 1, 2, or 3 independently selected R ^q substituents;

the subscript s is an integer of 0, 1, 2, 3 or 4; and

each subscript q is independently an integer of 1, 2, 3 or 4.

In some embodiments, provided herein is a compound having Formula (IIa):

or a pharmaceutically acceptable salt or a stereoisomer thereof. In some embodiments, Z ¹ is CR ¹ , Z ² is CR ² and Z ³ is CR ³ .

In some embodiments, provided herein is a compound having Formula (III):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² , X ³ , X ⁴ and X ⁶ are each independently C or N, with the proviso that no more than two of X ¹ , X ² , X ³ and X ⁴ are simultaneously N;

X ⁵ is C, N, O or S;

is a single or a double bond to maintain the fused 5- and 6-membered rings being aromatic.

In some embodiments, provided herein is a compound having Formula (IIIa):

or a pharmaceutically acceptable salt or a stereoisomer thereof. In some embodiments provided herein is a compound having Formula (IV):

(IV) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² , X ³ and X ⁴ are each independently C or N, with the proviso that no more than two of X ¹ , X ² , X ³ and X ⁴ are simultaneously N.

In some embodiments, provided herein is a compound having Formula (IVa):

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In some embodiments, provided herein is a compound having Formula (V):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² , X ³ , X ⁴ , X ⁶ , X ⁷ and X ⁸ are each independently C or N, with the proviso that no more than three of X ⁴ , X ⁶ , X ⁷ and X ⁸ are simultaneously N.

In some embodiments, provided herein is a compound having Formula (Va):

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In some embodiments, provided herein is a compound having Formula (VI):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² , X ³ , X ⁴ and X ⁶ are each independently C or N, with the proviso that no more than three of X ¹ , X ² , X ³ , X ⁴ and X ⁶ are simultaneously N.

In some embodiments, provided herein is a compound having Formula (VIa):

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In some embodiments, provided herein is a compound having Formula (VII):

(

(VII) or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² and X ³ are each independently C or N; and

ring C ^A is aromatic and ring D is fused 5- or 6-membered heterocycloalkyl.

In some embodiments, provided herein is a compound having Formula (VIIa):

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In some embodiments, provided herein is a compound having Formula (VIII):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ is N or C;

X ² , X ³ , X ⁴ and X ⁶ are each independently C, N, O or to maintain the 5-membered ring A being aromatic.

In some embodiments, provided herein is a compound having Formula (VIIIa): VIIIa) or a pharmaceutically acceptable salt or a stereoisomer thereof.

In some embodiments, provided herein is a compound having Formula (IX):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

X ¹ , X ² and X ³ are each independently C or N;

X ⁴ is CR ²⁴ or N;

X ⁶ is CR ²⁵ or N;

or R ²⁴ and R ²⁵ together with the carbon atoms to which they are attached form a fused phenyl ring, a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, a fused 5- or 6- membered heteroaryl ring or a fused C _3-6 cycloalkyl ring, wherein the fused phenyl ring, fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C _3-6 cycloalkyl ring are each optionally substituted with 1, 2 or 3 R ^b substituents.

In some embodiments, provided herein is a compound having Formula (IXa):

or a pharmaceutically acceptable salt or a stereoisomer thereof. In some embodiments rovided herein is a com ound havin Formula (X):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein: X ¹ , X ² , X ⁶ and X ⁷ are each independently C or N.

In some embodiments, Z ¹ is CR ¹ , Z ² is CR ² and Z ³ is CR ³ .

X ¹ , X ² , X ³ , X ⁴ , X ⁶ , X ⁷ and X ⁸ are each independently C or N;

X ⁵ is C, N, O or S;

each R ²⁶ is independently selected from H, halo, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C1-6 haloalkyl, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C _6-10 aryl-C _1-4 alkyl-, C _3-10 cycloalkyl-C _1-4 alkyl-, (5-14 membered heteroaryl)-C1-4 alkyl-, (4-10 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, OR ^a , SR ^a , NHOR ^a , C(O)R ^a , C(O)NR ^a R ^a , C(O)OR ^a , OC(O)R ^a , OC(O)NR ^a R ^a , NHR ^a , NR ^a R ^a , NR ^a C(O)R ^a , NR ^a C(O)OR ^a , NR ^a C(O)NR ^a R ^a , C(=NR ^a )R ^a , C(=NR ^a )NR ^a R ^a ,

NR ^a C(=NR ^a )NR ^a R ^a , NR ^a C(=NOH)NR ^a R ^a , NR ^a C(=NCN)NR ^a R ^a , NR ^a S(O)R ^a , NR ^a S(O) ₂ R ^a , NR ^a S(O)2NR ^a R ^a , S(O)R ^a , S(O)NR ^a R ^a , S(O)2R ^a , and S(O)2NR ^a R ^a , wherein the C1-6 alkyl, C2-6 alkenyl, C _2-6 alkynyl, C _6-10 aryl, C _3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-14 membered heteroaryl)-C _1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C _1-4 alkyl- of R ²⁶ is optionally substituted with 1, 2, 3, 4 or 5 independently selected R ^b substituents; and

each subscript r i r of 1, 2, 3, 4, 5, 6 or 7. In some embodi lected from:

inde endentl selected R ⁶ substituents. ach of which is optionally substituted with 1 to 5 independently selected R ⁶ substituents.

lected from:

of which is optionally substituted with 1 to 5 independently selected R ⁶ substituents.

ach of which is optionally substituted with 1, 2, 3, 4 or 5 independently selected R ⁶ substituents. In some embodiments, ring lected from:

ed R ⁵ substituents.

In some embodiments

ach of which is optionally substituted with 1, 2 or 3 independently selected R ³¹ substituents.

In some embodiments, L ¹ is a bond,–O-, -NHC(O)-, -NH-,-CH2NH-, or–CH2-. In some embodiments, L ² is a bond.

In some embodiments, L ³ is a bond,–O-, -NHC(O)-, -NH-,-CH2NH-, or–CH2-. In some embodiments, provided herein is a compound of Formula (XI):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

L ¹ is a bond, O, -NR ¹³ -, or -CH=CH-;

ring A is

wherein indicates the point of attachment of ring A to L ¹ ;

each R ¹³ is independently H, C1-6 haloalkyl or C1-6 alkyl;

R ⁴ is halo or C _1-6 alkyl;